Literature DB >> 1826193

Lung vascular injury after administration of viable hemolysin-forming Escherichia coli in isolated rabbit lungs.

W Seeger1, R Obernitz, M Thomas, D Walmrath, N Suttorn, I B Holland, F Grimminger, B Eberspächer, F Hugo, S Bhakdi.   

Abstract

Escherichia coli hemolysin, a transmembrane pore-forming exotoxin, is considered an important virulence factor. In the present study, the possible significance of hemolysin production was investigated in a model of septic lung failure through infusion of viable bacteria in isolated rabbit lungs; 10(4) to 10(7) E. coli/ml perfusate caused a dose- and time-dependent appearance of hemolysin, accompanied by release of potassium, thromboxane A2, and PGI2 into the perfusate. Concomitantly, marked pulmonary hypertension developed. Inhibitor studies suggested that the pressor response was predominantly mediated by pulmonary thromboxane generation. Administration of hemolysin-forming E. coli additionally caused a protracted, dose-dependent increase in the lung capillary filtration coefficient, followed by severe edema formation. The permeability increase was independent of lung prostanoid generation. An E. coli strain that releases an inactive form of hemolysin completely failed to provoke the described biophysical and biochemical responses. Preapplication of 2 x 10(8) human granulocytes was without effect in the present experimental model. We conclude that the hemolysin produced by low numbers of E. coli organisms can provoke thromboxane-mediated pulmonary hypertension and severe vascular leakage. E. coli hemolysin and, possibly, other related cytolysins may thus contribute directly to the pathogenesis of acute respiratory failure under conditions of sepsis or pneumonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826193     DOI: 10.1164/ajrccm/143.4_Pt_1.797

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Initial characterization of the hemolysin stachylysin from Stachybotrys chartarum.

Authors:  S J Vesper; M L Magnuson; D G Dearborn; I Yike; R A Haugland
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 2.  Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection.

Authors:  S Bhakdi; F Grimminger; N Suttorp; D Walmrath; W Seeger
Journal:  Med Microbiol Immunol       Date:  1994-07       Impact factor: 3.402

3.  Clinical Aspects of Acute Lung Insufficiency (ALI/TRALI).

Authors:  Matthias Hecker; Hans-Dieter Walmrath; Werner Seeger; Konstantin Mayer
Journal:  Transfus Med Hemother       Date:  2008-03-10       Impact factor: 3.747

4.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.

Authors:  Gustavo Matute-Bello; Gregory Downey; Bethany B Moore; Steve D Groshong; Michael A Matthay; Arthur S Slutsky; Wolfgang M Kuebler
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05       Impact factor: 6.914

5.  In vivo cytokine response to Escherichia coli alpha-hemolysin determined with genetically engineered hemolytic and nonhemolytic E. coli variants.

Authors:  A K May; R G Sawyer; T Gleason; A Whitworth; T L Pruett
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Stachylysin may be a cause of hemorrhaging in humans exposed to Stachybotrys chartarum.

Authors:  Stephen J Vesper; Mary Jo Vesper
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Immunocytochemical localization of stachylysin in Stachybotrys chartarum spores and spore-impacted mouse and rat lung tissue.

Authors:  L Gregory; T G Rand; D Dearborn; I Yike; S Vesper
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

8.  Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin.

Authors:  D Walmrath; H A Ghofrani; S Rosseau; H Schütte; A Cramer; W Kaddus; F Grimminger; S Bhakdi; W Seeger
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.